INBRX-106 is under clinical development by Inhibrx Biosciences and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INBRX-106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INBRX-106 overview
INBRX-106 is under development for the treatment of solid tumors including non-small cell lung cancer, uveal melanoma, esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer, head and neck squamous cell carcinoma, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, laryngeal cancer, gastrointestinal stromal tumor, gastric or gastro-esophageal junction adenocarcinoma, nasopharyngeal cancer, renal cell carcinoma, nasopharyngeal cancer, cervical cancer, gastrointestinal tumor, urothelial (transitional) cell carcinoma, triple-negative breast cancer, small cell lung cancer and hematological malignancies. The drug candidate is an optimized, single domain antibody (sdAb)-based hexavalent agonist of OX40.The drug candidate is a multivalent constitutive agonist. It acts by targeting the OX40 ligand. The drug candidate is developed based on a single domain antibody (sdAb) platform.
Inhibrx Biosciences overview
Inhibrx Biosciences is a biopharmaceutical company that primarily focuses on the development of novel biologic therapeutic candidates for the treatment of cancer and infectious diseases. The company is headquartered in La Jolla, California, the US.
For a complete picture of INBRX-106’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
